What are the clinical characteristics, experiences, and outcomes of transgender patients with cancer?
In this case series study of 37 transgender patients with cancer, most required multimodal therapy, and 16 patients received gender-affirming hormone therapy or surgery after their cancer diagnosis. Pronouns used were documented by only 4 oncologic practitioners; the medical records of 5 patients contained documented discussion that acknowledged the interaction between cancer treatment and their gender-affirming care.
Transgender patients develop a wide range of cancers, and many of them occur before gender-affirming care; however, documentation by oncologic practitioners suggests a need for acknowledgment of pronouns used by the patient and discussion surrounding the association of cancer treatment with gender-affirming care.
More than 1 million people in the US identify as transgender; however, few studies have examined the experiences and outcomes of transgender patients with cancer.
To examine clinical characteristics, experiences, and outcomes of transgender patients with cancer.
Design, Setting, and Participants
This retrospective case series assessed transgender patients with at least 1 cancer diagnosis who were evaluated at Dana-Farber Cancer Institute or Brigham and Women’s Hospital in Boston, Massachusetts, between January 1, 2005, and December 31, 2019.
Main Outcomes and Measures
Demographic, clinical, and treatment characteristics for all patients and documentation by oncologic practitioners of important aspects of providing gender-affirming care, including pronouns used by the patient, were recorded.
A total of 37 transgender patients with cancer were assessed (mean [SD] age, 38.9 [21.8] years at first cancer diagnosis). Fifteen patients (40.5%) had hematologic malignant cancers, and 25 patients (67.6%) had solid malignant tumors. Sixteen patients (43.2%) initiated gender-affirming hormone therapy or surgery after their cancer diagnosis. Cancer treatment was frequently multimodal, with 24 patients (64.9%) receiving systemic therapy, 24 (64.9%) receiving surgery, and 20 (54.1%) receiving radiation therapy along with other cancer-directed treatment, such as cryoablation. Five patients (13.5%) had documentation from an oncologic practitioner that addressed a potential interaction between their gender-affirming care and their cancer treatment. Thirty-three patients had follow-up visits with oncologic practitioners after starting their transition. Of those patients, pronouns used were documented by a member of the oncologic team for 4 patients (12.1%). However, for 3 of the 4 patients, documentation did not consistently use patient-reported information. At the last follow-up, 5 patients (13.5%) had died of their disease, and 26 (70.3%) were living without disease.
Conclusions and Relevance
This case series study found that transgender patients were diagnosed with diverse cancers, and many initiated gender-affirming hormone therapy or surgery after their diagnosis. Documentation by oncologic practitioners infrequently included pronouns used by the patient or discussion surrounding the interactions between cancer treatment and gender-affirming care, signifying that urgent improvements are needed in cancer care for transgender patients.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Burns ZT, Bitterman DS, Perni S, et al. Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer. JAMA Oncol. 2021;7(1):e205671. doi:10.1001/jamaoncol.2020.5671
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: